AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
WASHINGTON -- Drug plans that participate in the new Medicare prescription drug benefit in 2006 will face higher hurdles than just meeting the formulary guidelines being set by the U.S. Pharmacopeia.
"It's only the beginning of the review process--it's not the end of the review process," Bob Donnelly, who is the director of the Medicare Drug Benefit Group at the Centers for Medicare and Medicaid Services, said at a meeting on Medicare and Medicaid sponsored by America's Health Insurance Plans.
The 2003 Medicare Modernization Act called on U.S. Pharmacopeia (USP) to develop model guidelines that pharmaceutical benefit managers and prescription drug plans could use as a frame-work to design their own Part D formularies.
The draft USP guidelines, which were released in August, have come under fire from physicians and patient advocates, who say that organization of classes and categories in the draft would not require drug plans to cover critical medications such as statins, glitazones, and selective serotonin reuptake inhibitors.
But ...
Source: HighBeam Research, CMS to review medicare drug formularies.(Practice Trends)